Impilo
Impilo is a private equity firm established in 2017 and based in Stockholm, Sweden, with an additional office in Copenhagen, Denmark. The firm specializes in buyouts and growth capital, focusing exclusively on the healthcare sector, which includes pharmaceutical, medical technology, medical devices, care services, and preventative care. Impilo primarily targets companies located in the Nordic region, typically investing between SEK 100 million and SEK 1000 million in businesses with revenues ranging from SEK 200 million to SEK 1.5 billion. While the firm generally seeks to acquire a majority stake, it is also open to minority investments. Impilo primarily focuses on unlisted companies but may consider public investments if a controlling position is attainable.
Operator of a pre-clinical research organization based in Lille Skensved, Denmark. The company specializes in product development services within the pharmaceutical and medical device industries, enabling its clients to progress their drug or device development based on solid data towards technical and scientific standards.
Operator of a pre-clinical research organization based in Lille Skensved, Denmark. The company specializes in product development services within the pharmaceutical and medical device industries, enabling its clients to progress their drug or device development based on solid data towards technical and scientific standards.
Mallax aims to invest significant capital and resources for the right acquisition opportunities in Europe. The company aims to build a portfolio of established pharmaceuticals and OTC products for customers and patients across Europe through acquisitions and collaborations in the healthcare sector. It was formed through the partnership of Anders Larnholt, a pharma executive and entrepreneur, and Impilo, a Swedish investment company focused on healthcare and Nordic based companies.
Cavidi AB is a Swedish biotech company specializing in viral load solutions for monitoring human immunodeficiency virus (HIV). Founded in 1984 as a spin-off from Uppsala University, Cavidi develops products such as the ZIVA Viral Load system, designed for medium throughput in district hospitals, and the ExaVIR Load, a near-patient monitoring solution. The company also provides the ExaVIR drug for HIV treatment, as well as research tools like reverse transcriptase activity kits and viral titer measurement services. By offering efficient diagnostics, Cavidi supports the management of antiretroviral therapy, helping patients with HIV to maintain a normal lifespan while reducing treatment costs and the spread of the virus. The company's clientele includes hospitals, patient clinics, private laboratories, the pharmaceutical industry, and research institutions globally. Cavidi is headquartered in Uppsala, Sweden, with additional sales offices in South Africa, India, and the United States.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at
support@teaserclub.com. Your feedback is most welcome.